| Literature DB >> 28386563 |
Pongsathorn Chotikasemsri1, Boonsin Tangtrakulwanich2, Surasak Sangkhathat3.
Abstract
The purpose of this study was to investigate whether LED light at different wavelengths affects the expression profile of 143 cancer predisposition genes in both diabetic and normal human fibroblasts. In this study, both diabetic and normal fibroblast cell lines were cultured and irradiated with red (635 nm), green (520 nm), and blue (465 nm) LED light for 10 minutes at 0.67 J/cm2 each. After that, mRNA from all cell lines was extracted for microarray analysis. We found that green light activates EPHB2, KIT, ANTXR2, ESCO2, MSR1, EXT1, TSC1, KIT, NF1, BUB1B, FANCD2, EPCAM, FANCD2, NF, DIS3L2, and RET in normal fibroblast cells, while blue and red light can upregulate RUNX1, PDGFRA, EHBP1, GPC3, AXIN2, KDR, GLMN, MSMB, EPHB2, MSR1, KIT, FANCD2, BMPR1A, BUB1B, PDE11A, and RET. Therefore, genetic screening before phototherapy treatment may be required.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28386563 PMCID: PMC5366218 DOI: 10.1155/2017/7604861
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
There are 143 predisposition genes that have been widely used for SNP detection of various types of cancer.
| AIP | APC | BAP1 | BRCA2 |
| AKT1 | ASCC1 | BARD1 | BRIP1 |
| ALK | ATM | BLM | BUB1B |
| ANTXR1 | ATR | BMPR1A | CD96 |
| ANTXR2 | AXIN2 | BRCA1 | CDC73 |
| CDH1 | FANCI | MUTYH | RUNX1 |
| CDK4 | FANCL | NBN | SBDS |
| CDKN1B | FANCM | NDUFA13 | SDHA |
| CDKN2A | FH | NF1 | SDHAF2 |
| CHEK1 | FLCN | NF2 | SDHB |
| CHEK2 | GALNT12 | NTRK1 | SDHC |
| CYLD | GATA2 | PALB2 | SDHD |
| CYP21A2 | GL13 | PALLD | SLX4 |
| DDB2 | GLMN | PDE11A | SMAD4 |
| DICER1 | GPC3 | PDGFRA | SMARCA4 |
| DIS3L2 | HFE | PIK3CA | SMARCB1 |
| DKC1 | HRAS | PMS2 | STK11 |
| EHBP1 | KDR | POLD1 | SUFU |
| EPCAM | KIF1B | POLE | TERT |
| EPHB2 | KIT | POLH | TGFBR1 |
| ERCC2 | KLHDC8B | POU6F2 | TINF2 |
| ERCC3 | LIG4 | PRKAR1A | TMC6 |
| ERCC4 | LYST | PTCH1 | TMC8 |
| ERCC5 | MAX | PTCH2 | TMEM127 |
| ERCC6 | MC1R | PTEN | TP53 |
| ESCO2 | MEN1 | RAD50 | TSC1 |
| EXT1 | MET | RAD51B | TSC2 |
| EXT2 | MITE | RAD51C | UROD |
| FAH | MLH1 | RAD51D | VHL |
| FANCA | MLH3 | RB1 | WAS |
| FANCB | MRE11A | RECQL4 | WRN |
| FANCC | MSH2 | RET | WT1 |
| FANCD2 | MSH6 | RHBDF2 | XPA |
| FANCE | MSMB | RNASEL | XPC |
| FANCF | MSR1 | RSPO1 | XRCC3 |
| FANCG | MTAP | RTEL1 |
Assigned abbreviations for each condition.
| Untreated | Treated with red light | Treated with green light | Treated with blue light |
|---|---|---|---|
| NCL control | NCL red | NCL green | NCL blue |
| DMCL control | DMCL red | DMCL green | DMCL blue |
Figure 137 out of 143 genes were significantly up- or downregulated with more than 2-fold differences after irradiation with red, green, or blue light in normal skin fibroblast cells (p < 0.05).
Figure 258 out of 143 genes were significantly up- and downregulated for 2-fold differences after irradiation with red, green, or blue light in diabetic fibroblast cells (p < 0.05).
Summary of genes that were affected from each treatment (p < 0.05).
| Blue | Green | Red | |||||
|---|---|---|---|---|---|---|---|
| NCL | Up | BUB1B | FANCD2 | EPHB2 | BUB1B | FANCB | FANCD2 |
| MSR1 | ERCC5 | KIT | EPCAM | POLH | SUFU | ||
| ANTXR2 | FANCD2 | KIT | TMC8 | ||||
| ESCO2 | NF1 | POLE | MSR1 | ||||
| MSR1 | DIS3L2 | BUB1B | RET | ||||
| EXT1 | RET | DIS3L2 | |||||
| TSC1 | |||||||
| Down | DKC1 | CD96 | DKC1 | MSH6 | NF1 | ERCC5 | |
| HFE | RAD51B | ERCC5 | PDE11A | NTRK1 | FLCN | ||
| MSR1 | ERCC5 | GPC3 | TP53 | MSR1 | TP53 | ||
| FLCN | TP53 | ANTXR1 | |||||
| MSH6 | |||||||
|
| |||||||
| DMCL | Up | RUNX1 | PDE11A | EPHB2 | RUNX1 | GLMN | |
| FANCD2 | RET | SDHC | PDGFRA | MSMB | |||
| BMPR1A | KDR | NF1 | EHBP1 | EPHB2 | |||
| BUB1B | GPC3 | MSR1 | |||||
| EPHB2 | AXIN2 | KIT | |||||
| EHBP1 | KDR | ||||||
| Down | NF1 | ERCC5 | CD96 | GALNT12 | GPC3 | DKC1 | |
| KIT | DKC1 | PTCH2 | ERCC5 | TMC6 | TP53 | ||
| GALNT12 | TP53 | AXIN2 | KIT | PTCH1 | |||
| TMC6 | NF1 | NF1 | |||||
| EPCAM | DKC1 | ||||||
| MSH6 | TP53 | ||||||
Cancer-related predisposition genes that were overexpressed after blue, green, or red light irradiation in normal healthy fibroblast cells (nondiabetic patients) (p < 0.05).
| Light condition | Overexpressed genes after irradiation | Possible cancers affected |
|---|---|---|
| Blue | BUB1B | Brain and lung cancer |
| ERCC5 | Ovarian cancer | |
| FANCD2 | Breast cancer and Fanconi anemia | |
| MSR1 | Prostate cancer and Barrett's esophagus/esophageal adenocarcinoma | |
|
| ||
| Green | ANTXR2 | Hyaline fibromatosis syndrome and hyalinosis, inherited systemically (its related pathways are infectious disease and uptake and actions of bacterial toxins) |
| BUB1B | Brain and lung cancers | |
| DIS3L2 | Perlman syndrome and Wilms' tumor susceptibility-5 | |
| EPCAM | Endometrial cancer, biliary tract cancer, and skin cancer | |
| ESCO2 | Roberts syndrome and SC phocomelia syndrome | |
| EPHB2 | Prostate cancer/brain cancer susceptibility, somatic and prostate cancer | |
| EXT1 | Chondrosarcoma and exostoses, multiple, type 1 | |
| FANCD2 | Breast cancer and Fanconi anemia | |
| KIT | Endometrial cancer as a gastrointestinal stromal tumor | |
| MSR1 | Prostate cancer and Barrett's esophagus/esophageal adenocarcinoma | |
| NF1 | Neurofibromatosis-Noonan syndrome and neurofibromatosis, type 1 | |
| RET | Multiple endocrine neoplasia iia and medullary thyroid carcinoma, familial | |
| TSC1 | Tuberous sclerosis-1 and lymphangioleiomyomatosis | |
|
| ||
| Red | BUB1B | Brain and lung cancer |
| DIS3L2 | Perlman syndrome and Wilms' tumor susceptibility-5 | |
| FANCB | Fanconi anemia, complementation group B, and Fanconi anemia, complementation group A | |
| FANCD2 | Breast cancer and Fanconi anemia | |
| KIT | Endometrial cancer as a gastrointestinal stromal tumor | |
| MSR1 | Prostate cancer and Barrett's esophagus/esophageal adenocarcinoma | |
| POLE | FILS syndrome and colorectal cancer 12 | |
| POLH | Xeroderma pigmentosum, variant type and POHL-related xeroderma pigmentosum | |
| RET | Multiple endocrine neoplasia iia and medullary thyroid carcinoma, familial | |
| SUFU | Medulloblastoma and basal cell nevus syndrome | |
| TMC8 | Epidermodysplasia verruciformis and superficial mycosis | |
Cancer-related predisposition genes that were overexpressed after blue, green, or red light irradiation in diabetic fibroblast cells (p < 0.05).
| Light condition | Overexpressed genes after irradiation | Possible cancers affected |
|---|---|---|
| Blue | BUB1B | Brain and lung cancers |
| BMPR1A | Polyposis syndrome, hereditary mixed, 2 and polyposis, juvenile intestinal | |
| EHBP1 | Prostate cancer, hereditary, 12 and prostate cancer | |
| EPHB2 | Prostate cancer/brain cancer susceptibility, somatic and prostate cancer | |
| FANCD2 | Breast cancer and Fanconi anemia | |
| KDR | Hemangioma, capillary infantile and hemangioma | |
| PDE11A | Pigmented nodular adrenocortical disease, primary, 2 and primary pigmented nodular adrenocortical disease | |
| RET | Multiple endocrine neoplasia iia and medullary thyroid carcinoma, familial | |
| RUNX1 | Platelet disorder, familial, with associated myeloid malignancy and isolated delta-storage pool disease (among its related pathways are endometrial cancer and chronic myeloid leukemia) | |
|
| ||
| Green | EPHB2 | Prostate cancer/brain cancer susceptibility, somatic and prostate cancer |
| NF1 | Neurofibromatosis-Noonan syndrome and neurofibromatosis, type 1 | |
| SDHC | Paragangliomas 3 and paraganglioma and gastric stromal sarcoma (among its related pathways are Alzheimer's disease and carbon metabolism) | |
|
| ||
| Red | AXIN2 | Oligodontia-colorectal cancer syndrome and colorectal cancer |
| EHBP1 | Prostate cancer, hereditary, 12 and prostate cancer | |
| EPHB2 | Prostate cancer/brain cancer susceptibility, somatic and prostate cancer | |
| GLMN | Glomuvenous malformations and glomangioma | |
| GPC3 | Simpson-Golabi-Behmel syndrome, type 1 and Wilms tumor susceptibility-5 | |
| KDR | Hemangioma, capillary infantile and hemangioma | |
| KIT | Endometrial cancer in gastrointestinal stromal tumor | |
| MSMB | Prostate cancer, hereditary, 13 and prostate cancer | |
| MSR1 | Prostate cancer and Barrett esophagus/esophageal adenocarcinoma | |
| PDGFRA | Gastrointestinal stromal tumor and hypereosinophilic syndrome, idiopathic, resistant to imatinib | |
| RUNX1 | Platelet disorder, familial, with associated myeloid malignancy and isolated delta-storage pool disease (among its related pathways are endometrial cancer and chronic myeloid leukemia) | |